Roflumilast    (DrugBank: Roflumilast)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
84サルコイドーシス1
299嚢胞性線維症5

84. サルコイドーシス [臨床試験数:143,薬物数:221(DrugBank:79),標的遺伝子数:82,標的パスウェイ数:165
Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 143 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01830959
(ClinicalTrials.gov)
April 201310/4/2013Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)SarcoidosisDrug: Roflumilast;Drug: PlaceboUniversity of CincinnatiThe Cleveland Clinic;University of Pittsburgh;University of Illinois at Chicago;Henry Ford Health System;Albany Medical CollegeActive, not recruiting18 Years70 YearsBoth50Phase 4United States

299. 嚢胞性線維症 [臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 1,592 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04322929
(ClinicalTrials.gov)
December 30, 202024/3/2020Roflumilast in Non-CF Bronchiectasis Study (2019)Anti-inflammatory Effects of Roflumilast Treatment for 12 Weeks in Stable-state Non-cystic Fibrosis BronchiectasisNon-cystic Fibrosis BronchiectasisDrug: Roflumilast Oral TabletThe University of Hong KongNULLNot yet recruiting18 YearsN/AAll27Phase 2Hong Kong
2NCT03988816
(ClinicalTrials.gov)
December 6, 201914/6/2019Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With BronchiectasisEffect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Non-cystic Fibrosis Bronchiectasis: a Cross-over, Unicentric, Double-blind and Placebo-controlled StudyBronchiectasis AdultDrug: Roflumilast;Drug: Placebo oral tabletUniversity of Sao Paulo General HospitalFAPESP - Fundação de Apoio à Pesquisa do Estado de São PauloRecruiting18 YearsN/AAll30Phase 2Brazil
3NCT04090294
(ClinicalTrials.gov)
October 1, 201921/8/2019Assessment of Early Outcomes of Roflumilast in Patients With Non Cystic Fibrosis BronchiectasisAssessment of Early Outcomes of Roflumilast in Patients With Non Cystic Fibrosis BronchiectasisBronchiectasisDrug: RoflumilastAssiut UniversityNULLNot yet recruiting18 Years75 YearsAll35Early Phase 1NULL
4NCT03428334
(ClinicalTrials.gov)
May 10, 201826/1/2018Roflumilast in Non-CF Bronchiectasis StudyA 4-week Single-arm Study of Roflumilast in Stable-state Non-cystic Fibrosis BronchiectasisNon-cystic Fibrosis BronchiectasisDrug: Oral roflumilastThe University of Hong KongNULLCompleted18 YearsN/AAll20Phase 2Hong Kong
5NCT04122547
(ClinicalTrials.gov)
January 20158/10/2019Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis BronchiectasisEfficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis: a Randomized Double-blind Placebo-controlled TrialExacerbation Copd;Bronchiectasis;Lung Function DecreasedDrug: Roflumilast;Drug: PlaceboPrince of Songkla UniversityNULLCompleted18 Years80 YearsAll40Phase 3Thailand